🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Alefacept is a new anti-psoriatic drug within the group of the so-called bi...
Status
Completed
Location
Medical University of Graz
Start Date
2004-02
Trial ID
NCT00407342
Treatments Being Tested
Golimumab, a TNF-alpha antibody, has been approved in the EC and USA for th...
Status
Terminated
Location
Medical University of Graz
Start Date
2010-03
Trial ID
NCT01088698
Treatments Being Tested
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antib...
Status
Unknown
Location
Medical University of Graz, Department of Dermatology
Start Date
2008-03
Trial ID
NCT00638469
Treatments Being Tested
Etanercept, a biological antipsoriatic drug with anti-tumor-necrosis factor...
Status
Completed
Location
Medical University of Graz, Department of Dermatology
Start Date
2006-08
Trial ID
NCT00550030
Treatments Being Tested
Ustekinumab, an IL-12/23 antibody has been approved in the E.C. and U.S.A. ...
Status
Completed
Location
Medical University, Department of Dermatology
Start Date
2009-03
Trial ID
NCT00870285
Treatments Being Tested
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antib...
Status
Completed
Location
Medical University of Graz, Department of Dermatology
Start Date
2008-03
Trial ID
NCT00638261
Treatments Being Tested